ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta ...

The FDA has granted priority review to a new drug application (NDA) seeking the approval of sonrotoclax (BGB-11417; BeOne ...

On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) ...

European Commission grants conditional marketing approval for Roche’s Lunsumio subcutaneous for R/R follicular lymphoma: Basel Thursday, November 20, 2025, 12:00 Hrs [IST] Roche ...

Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that typically becomes harder to treat each time a patient relapses1,2Lunsumio ...

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) assessment at treatment completion provides superior prognostic accuracy compared with PET in large B-cell lymphoma. The CLARITY assay ...

Strong willed. Head strong. Loving and brave. A fighter. Those are some of the phrases Nikki Montney used to describe her 16-year-old daughter. A junior at Flushing High School, Maddie Walker was ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates (ADCs)—in a Lunsumio-Polivy regimen in large B-cell lymphoma (LBCL). The ...